Appendix 0: Sample Request for an Unlisted Drug Product, IM Testosterone

UTILATIO and	istry of Healt Long-Term	Care 5700 Toror	ptional Access F Yonge Street 3 ⁿ nto ON M2M 4K	floor Exce	ptional Access	s Progra	•	
Please fax completed form and Program Branch (EAPB), 3 rd flo http://www.health.gov.on.ca/en	oor, 5700 You nglish/public/	nge Street, T forms/form_	oronto ON M2I menus/odb_fm	If 4K5. For copies of this html	s and other EAP	forms, p	please visit	
request.	intended to fac	litate requests	for drugs under the	e Exceptional Access Program			t Formulary under Section 16 of the dditional documentation to support the	
Please ensure that all appropriate info		n section is pro	vided to avoid dela	-	4: 4 l f	4:		
Section 1 – Prescriber Inf	Initial	Last name		Section 2 – Pa	tient informa	Initial	Last name	
sample	IIIIIai	Last Hairie		sample		IIIIIai	Last Hame	
Mailing Address Street no. Street name				Health Number				
City			Postal code					
Fax no. Telephon		Telephone	no.	Date of birth (yyyy/	Date of birth (yyyy/mm/dd)			
New request	Rei	newal of exis	ting EAP appro	oval (specify EAP#)			_	
Section 3 – Drug Reques		J. OXIO	9	. (-,,)				
Requested drug product Depo-testosterone				DIN 00030783				
Strength / Dosage form		Frequency of administration						
100 mg/mL, 1 mL IM, may require titration				2/ 2 1	weekly, may require adjustment			
Expected start date				Duration of therapy				
				indefinite				
Section 4 – Diagnosis an Diagnosis for which the drug is re		for Use						
Gender Dysphoria Reason for use over formulary alt	tornativos:							
No alternative on formulary	terriatives.							
If the patient is currently taking the					of its efficacy:			
Definitive improvement in ps	sychosocial	functioning	and decrease i	n Gender Dysphoria				
Section 5 - Current and /								
Please provide details of alternatives (listed drugs and Name of drug		or non-drug thei Dosage	Approximate	on: Reason(s) why formulary alternatives are not appropriate				
(indicate if currently or p	oreviously tak	7	Doodgo	timeframe of therapy	· ioucon(o) iiii)		y anomalivos aro not appropriato	
N/A	<u> </u>	_ current						
		previous						
	L	current previous						
		<u> </u>						
	L	_ current						
	L	previous						
	L	current previous						
	L	_ previous						
b) Provide patient's concomita	ant drug thera		conditions:					
Section 6 – Clinical Infor	mation	pies for other		erum drug levels. laboratr	pry results):			
Section 6 – Clinical Information Please provide relevant medical	mation data (e.g. cul	ture and sens	sitivity reports, se	-	pry results):			
Section 6 – Clinical Information Please provide relevant medical Patient has been diagnosed when the information on this form is collect Drug Benefit Act. R.S.O. 1990c.O.10	mation data (e.g. cul rith Gender I	ture and sens	sitivity reports, so nd qualifies fo Personal Health In e with PHIPA. as s	or hormone therapy formation Protection Act, 20 set out in the Ministry of Heal	04, S.O. 2004, c.3,	Care "Stat	ement of Information Practices", which	
Section 6 – Clinical Infor Please provide relevant medical Patient has been diagnosed w The information on this form is collect	mation data (e.g. cul rith Gender I ted under the a and will be use on.ca. If you he coess Program	ture and sens	sitivity reports, so nd qualifies fo Personal Health In e with PHIPA. as s	or hormone therapy formation Protection Act, 20 set out in the Ministry of Heal	04, S.O. 2004, c.3,	Care "Stat		